| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 12/06/2001 | CA2410643A1 Hygromycin a derivatives for the treatment of bacterial and protozoal infections |
| 12/06/2001 | CA2410591A1 Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases |
| 12/06/2001 | CA2410589A1 Pharmaceutical compositions of 2'-deoxy-2'-(fluoromethylene)cytidine |
| 12/06/2001 | CA2410543A1 Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens |
| 12/06/2001 | CA2410453A1 Neuroprotective peptides |
| 12/06/2001 | CA2410252A1 Diagnosis and treatment of herpes infections |
| 12/06/2001 | CA2410084A1 Transporters and ion channels |
| 12/06/2001 | CA2410033A1 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 12/06/2001 | CA2409964A1 Peptide substrate identified by type bont/b botulinus toxin and use thereof for assaying and/or detecting said toxin or corresponding inhibitors |
| 12/06/2001 | CA2409924A1 Convergent combinatory peptide libraries and their use for vaccination against hepatitis c virus |
| 12/06/2001 | CA2409359A1 Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity |
| 12/06/2001 | CA2409311A1 Regulators of apoptosis |
| 12/06/2001 | CA2409267A1 Use of interleukin-4 antagonists and compositions thereof |
| 12/05/2001 | EP1160320A1 Use of hTAFII80 and isoforms thereof for inducing apoptosis |
| 12/05/2001 | EP1160255A1 Monovalent antibody fragments |
| 12/05/2001 | EP1160240A1 Guanylhydrazones for treating inflammatory conditions |
| 12/05/2001 | EP1159969A1 Composition vaccinale |
| 12/05/2001 | EP1159968A1 Attenuated strains of Dengue virus and their use in a vaccine composition |
| 12/05/2001 | EP1159962A1 Liposome preparations |
| 12/05/2001 | EP1159951A1 Use of exogenous lactic bacteria strain against Actinomyces naeslundii-related diseases |
| 12/05/2001 | EP1159437A2 Method to improve translation of polypeptides by using untranslated regions from heat-shock proteins |
| 12/05/2001 | EP1159427A1 Gp120 mutants and biological applications |
| 12/05/2001 | EP1159417A2 Polynucleotides and proteins encoded thereby |
| 12/05/2001 | EP1159405A2 Viral particles which are released after the infection with the human cytomegalovirus and the use of said particles as a vaccine |
| 12/05/2001 | EP1159404A2 Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
| 12/05/2001 | EP1159300A2 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 12/05/2001 | EP1159298A1 Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv |
| 12/05/2001 | EP1159297A2 Hiv related peptides |
| 12/05/2001 | EP1159291A1 C-terminal modified (n-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 12/05/2001 | EP1159286A1 Tumor necrosis factor receptors 6 alpha and 6 beta |
| 12/05/2001 | EP1159284A1 33 human secreted proteins |
| 12/05/2001 | EP1159279A2 4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents |
| 12/05/2001 | EP1159278A2 Inhibitors of aspartyl protease |
| 12/05/2001 | EP1159277A1 Crystal modification d of 8-cyano-1-cyclopropyl-7- (1s, 6s- 2,8- diazabicyclo- 4.3.0] nonan-8-yl) -6-fluoro -1,4-dihydro -4-oxo -3-quinoline carboxylic acid |
| 12/05/2001 | EP1159264A2 INHIBITORS OF FACTOR Xa |
| 12/05/2001 | EP1159256A1 Sphingoid base derivatives and uses thereof |
| 12/05/2001 | EP1159006A2 Water-soluble compositions of bioactive lipophilic compounds |
| 12/05/2001 | EP1159005A1 Pharmaceutical combination of antiviral agents |
| 12/05/2001 | EP1159001A2 MULTI-COMPONENT VACCINE COMPRISING AT LEAST THREE ANTIGENS TO PROTECT AGAINST DISEASE CAUSED BY $i(HAEMOPHILUS INFLUENZAE) |
| 12/05/2001 | EP1158996A1 Novel amide derivatives as growth hormone secretagogues |
| 12/05/2001 | EP1158993A1 Bacterial membrane fractions with adjuvant effect |
| 12/05/2001 | EP1158990A1 Administration of an anti-endotoxin drug by intravenous infusion |
| 12/05/2001 | EP1158986A1 Protease inhibitors |
| 12/05/2001 | EP1158984A1 Inhibitors of prenyl-protein transferase |
| 12/05/2001 | EP1158983A1 Inhibitors of prenyl-protein transferase |
| 12/05/2001 | EP1158982A2 Inhibitors of prenyl-protein transferase |
| 12/05/2001 | EP0951563A4 A new eia test using non-dentured hiv antigen for early detection of hiv infection |
| 12/05/2001 | EP0911327B1 Novel pyridonecarboxylic acid derivatives or their salts and antibacterial agent comprising the same as the active ingredient |
| 12/05/2001 | EP0814815A4 Poly(hydroxy acid)/polymer conjugates for skin applications |
| 12/05/2001 | EP0769056B1 NON-SPLICING VARIANTS OF gp350/220 |
| 12/05/2001 | EP0749437B1 Pharmaceutical uses of steroid derivatives |
| 12/05/2001 | EP0721337B1 Oral formulations of an antifungal |
| 12/05/2001 | EP0605432B1 Induction of cytolytic t-lymphocytes with cytomegalovirus polypeptides |
| 12/05/2001 | CN1325453A Vancoresmycin, a process for its production and its use as a pharmaceutical |
| 12/05/2001 | CN1325452A Method for the preparation of quercetin and isoquercetin derivatives |
| 12/05/2001 | CN1325441A Modified exosomes and uses |
| 12/05/2001 | CN1325393A Method for producing luteolin and luteolin derivatives |
| 12/05/2001 | CN1325390A 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| 12/05/2001 | CN1325389A 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| 12/05/2001 | CN1325387A 2,4-disubstituted triazine derivatives |
| 12/05/2001 | CN1325311A Vaccine against sexually transmitted diseases |
| 12/05/2001 | CN1325309A Compounds, compositions and method for treating or preventing viral infections and associated diseases |
| 12/05/2001 | CN1325306A Pharmaceutical moxifloxacin preparation |
| 12/05/2001 | CN1325303A Tocopherols, tocotrienols, other chroman and side chain derivatives and uses |
| 12/05/2001 | CN1325299A Orally administered controlled drug delivery system providing temporal and spatial control |
| 12/05/2001 | CN1325270A Antimicrobial composition comprising an oxidoreductase and an enhancing agent of the N-hydroxy anilide-type |
| 12/05/2001 | CN1324660A Static water pressure deactivation and nanometer techn. treatment process of influenza virus to prepare lytic vaccine |
| 12/05/2001 | CN1324641A Compound honeysuckle tea and its prepn. |
| 12/05/2001 | CN1324607A Anti-fungus agent for local treatment of fungus infection of finger and its peripheral tissue and controllable releasable system of keratin-dissolving agnt |
| 12/05/2001 | CN1075816C Methods for in vivo reduction of nitric oxide levels and compositions sueful therefor |
| 12/05/2001 | CN1075722C Fungicidal compositions containing bifonazole |
| 12/04/2001 | US6326403 Cardiovascular disorders |
| 12/04/2001 | US6326402 Aromatic ester compound |
| 12/04/2001 | US6326395 Amidine or amide substituted furan derivatives |
| 12/04/2001 | US6326394 Calixarene tubes as cation receptors |
| 12/04/2001 | US6326391 Inhibitors of multidrug transporters |
| 12/04/2001 | US6326388 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| 12/04/2001 | US6326385 Administering poltassium channel modulator |
| 12/04/2001 | US6326364 Use of 5-aminosalicylates as antimicrobial agents |
| 12/04/2001 | US6326359 Adenosine A2A receptor agonists as antiinflammatory agents |
| 12/04/2001 | US6326353 123therapy for septic shock; administering polymyxin by injection |
| 12/04/2001 | US6326350 Genetic engineering |
| 12/04/2001 | US6326199 Hybridization and rnace activation in a cell with oligonucleotides |
| 12/04/2001 | US6326195 Recombinant retroviral vector |
| 12/04/2001 | US6326171 Hepatitis C E1 and E2 truncated polypeptides and methods of obtaining the same |
| 12/04/2001 | US6326170 Prokaryotic polynucleotides, polypeptides and their uses |
| 12/04/2001 | US6326152 Exposing nadh dehydrogenase-expressing cells to test compound; measuring expression or enzymatic activity of nadh dehydrogenase in cells; selecting compound that down-regulates nadh dehydrogenase expression or activity |
| 12/04/2001 | US6326151 Screening methods to identify agents that selectively inhibit hepatitis C virus replication |
| 12/04/2001 | US6326007 Genes responsible for pathogenesis completely or partially nonfunctional by modifying or deleting nef (negative effector) start codon; enhanced expression of cytokine and/or lymphokine; vaccines |
| 12/04/2001 | US6326004 Antiviral methods using fragments of human rhinovirus receptor (ICAM-1) |
| 12/04/2001 | US6326001 Recombinant vaccine for diseases caused by encapsulated organisms |
| 12/04/2001 | CA2217953C A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancers |
| 12/04/2001 | CA2208836C Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
| 12/04/2001 | CA2110260C Pyridonecarboxylic acid derivatives |
| 12/04/2001 | CA2053829C Vaccines against equine herpesviruses and the preparation thereof |
| 12/04/2001 | CA2046880C Substituted alkylamide derivatives of teicoplanin |
| 12/04/2001 | CA2040982C N-(3-fluoro-2-phosphonylmethoxypropyl) derivatives of purine and pyrimidine heterocyclic bases, their preparation and use |
| 11/29/2001 | WO2001090404A1 Drug screening systems and assays |
| 11/29/2001 | WO2001090363A1 Chimeric arterivirus-like particles |
| 11/29/2001 | WO2001090359A2 G-protein coupled receptors |